Kamil Drucis

机构：Gdańsk Medical University · ORCID：0000-0002-7251-3505

发表论文 41 篇 · 总被引 3492 次 · h-index 10

代表论文

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib (2014 · New England Journal of Medicine · 被引 2681)
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial (2015 · The Lancet Oncology · 被引 266)
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial (2018 · The Lancet Oncology · 被引 203)
3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma (2015 · European Journal of Cancer · 被引 80)
Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma (2016 · Annals of Oncology · 被引 74)
Simultaneous Determination of Na+, K+, Ca2+, Mg2+ and Cl− in Unstimulated and Stimulated Human Saliva Using All Solid State Multisensor Platform (2017 · Electroanalysis · 被引 31)